medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 6

<< Back Next >>

Med Int Mex 2020; 36 (6)

Severe pneumonia due to COVID-19 and administration of biological drugs

Herrera-García JC, Nuche-Salazar NP, Domínguez-Peregrina A, Reyes R, Arizpe-Bravo B

Language: Spanish
References: 24
Page: 888-894
PDF size: 216.23 Kb.


ABSTRACT

Background: In February 2020 World Health Organization (WHO) declared a pandemic for COVID-19 disease (coronavirus disease 2019). In the treatment, the evidence suggests the use of biological medications to counteract the so-called cytochemical storm in order to decrease systemic inflammation and therefore reduce morbidity and mortality.
Clinical cases: Six patients (four male, 66.6% and two women, 33.3%) with average age of 58.1 years (range: 41-71) with diagnosis of severe pneumonia due to COVID-19 and the administration of two implied treatments in the cytochemical storm, such as tocilizumab and ruxolitinib. This paper described their clinical evolution in an intensive care unit of a private hospital of Puebla, Puebla. The most important findings were: relieve at 48 hours in the clinical parameters and reduction of inflammation markers after the application of biological drugs. There were not adverse reactions.
Conclusions: The use of tocilizumab, ruxolitinib or both are medications that reduced systemic inflammation in patients with severe pneumonia due to COVID-19.


REFERENCES

  1. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. [Online].; 2020 [cited 2020 March 20. Available from: https://www.who.int/dg/speeches/detail/who-directorgeneral- s-remarks-at-the-media-briefing-on-2019-ncovon- 11-february-2020

  2. McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention [UpToDate]; 2020.

  3. Tao A, Zhenlu Y. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020. https://doi.org/10.1148/ radiol.2020200642

  4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033- 1034. https://doi.org/10.1016/S0140-6736(20)30628-0

  5. Zhang C, Wu Z, Li J, Zhao H, GQ W. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020. DOI: 10.1016/j.ijantimicag.2020.105954

  6. Fu B, Xu X, We H, et al. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020; 18 (164). https://doi.org/10.1186/s12967-020-02339-3

  7. Misra D, Agarwal V, Gasparyan A, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020. DOI: 10.1007/s10067-020-05073-9

  8. Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, Zileri Dal Verme L, Bernabei R, Tamburrini E, Cauda R, Gasbarrini A. Off-label use of tocilizumab in patients with SARS-CoV-2 infection J Med Virol 2020. DOI: 10.1002/jmv.25897

  9. Buonaguro FM, Puzanov I, Ascierto PA. Anti-IL6R role in treatment of COVID-19-related. ARDS J Transl Med 2020; 18 (1): 165. DOI: 10.1186/s12967-020-02333-9

  10. Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, Wang J, Zheng C. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Case Reports Blood Adv 2020; 4 (7): 1307-1310. DOI: 10.1182/bloodadvances. 2020001907

  11. Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E, Ivaturi K, Park E, Nguyen L, Wang B, Tonthat S, Rhee CM, Reddy U, Lau WL, Huang SS, Gohil S, Amin AN, Hsieh L, Cheng TT, Lee RA, Kalantar-Zadeh K. A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease. Am J Nephrol 2020; 1-6. DOI: 10.1159/000507417

  12. Zhao JP, Hu Y, Du RH. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia (in Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: E007. DOI: 10.3760/cma.j.issn.1001-0939.2020.0007

  13. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395 (10225): 683-684. DOI: 10.1016/S0140-6736(20)30361-5

  14. Kim AY, Gandhi RT. Coronavirus disease 2019 (COVID-19): Management in adults [UpToDate].; 2020.

  15. Tang N, Bai H, Chen X, GJ, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis. 2020. DOI: 10.1111/jth.14817

  16. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl J Med 2012;366:787-98.

  17. Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun 2017;85:58-63.

  18. Moore, BJB, June, CH. Cytokine release syndrome in severe COVID-19. Science 2020. https://doi.org/10.1126/ science.abb8925

  19. La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosée P. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation: Leukemia 2020. https://doi.org/10.1038/s41375-020-0891-0

  20. Zhang Y. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19), China CDC Weekly; 2020.

  21. World Health Organization. (2020). Global Surveillance for human infection with novel coronavirus (2019-nCoV): interim guidance, 31 January 2020. World Health Organization. https://apps.who.int/iris/handle/10665/330857. License: CC BY-NC-SA 3.0 IGO.

  22. Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARS-CoV-2 – SEPAR and other scientific societies [Spanish].

  23. Fumar em momentos do COVID-19 - Documento para profissionais de saúde [Portuguese] / Smoking in COVID-19 times - Document for healthcare providers [English] – Asociación Latinoamericana de Tórax (ALAT), Unión Internacional contra la tuberculosis y enfermedades respiratorias (La Unión), Sociedad Española de Neumología y Cirugía Torácica (SEPAR), et al.

  24. COVID-GRAM Risk Score - Predicts risk of critical illness in hospitalized COVID-19 patients. https://www.mdcalc. com/covid-19.




2020     |     www.medigraphic.com